Pediatrix Medical Group (MD) is back in focus after its latest Q1 update, where management reported improved profitability, stronger cash collections, reaffirmed 2026 EBITDA guidance, and highlighted continued growth in core neonatal and maternal-fetal care services.
See our latest analysis for Pediatrix Medical Group.
At a share price of US$23.01, Pediatrix Medical Group has a 1-year total shareholder return of 51.78% and a 3-year total shareholder return of 70.07%, while the 5-year total shareholder return is down 27.11%. This suggests that recent momentum has picked up following the Q1 update, acquisitions, and insider transactions.
If Pediatrix’s recent move has your attention, it can be useful to see what else is gaining interest in healthcare, starting with 29 healthcare AI stocks.
With Pediatrix now trading close to analyst targets and an intrinsic value estimate suggesting a large potential gap, the key question is whether recent optimism leaves upside on the table or whether the stock already reflects future growth.
Most Popular Narrative: 7.9% Overvalued
Compared with the last close at $23.01, the most followed narrative points to a fair value of $21.33, suggesting Pediatrix could be pricing in more than that framework supports today.
Ongoing operational improvements, such as enhancements in revenue cycle management and tightly controlled salary expenses, are improving working capital efficiency and holding down expense growth, supporting higher net earnings and cash flow conversion.
Want to see what happens when these cost controls meet slower top line assumptions and a moderating profit margin outlook? The tension between modest revenue growth, share count changes, and a lower future earnings multiple is what really shapes this fair value story.
Result: Fair Value of $21.33 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this outlook still hinges on successful portfolio restructuring and controlled salary costs. If these factors disappoint, they could pressure margins and unsettle the current valuation story.
Find out about the key risks to this Pediatrix Medical Group narrative.
Another View: Cash Flows Point in a Different Direction
The analyst narrative suggests Pediatrix is about 7.9% overvalued at $21.33, but the Simply Wall St DCF model points the other way, with an estimated future cash flow value of $59.26 per share, indicating a very large potential gap. Which framework do you trust more: the earnings multiple story or the cash flow math?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
With sentiment this mixed, it makes sense to quickly review the numbers, weigh both the concerns and the potential upside, and form your own stance using our breakdown of 3 key rewards and 2 important warning signs
Ready for more investment ideas?
If Pediatrix has put healthcare on your radar, do not stop here. Widen your watchlist with a few carefully filtered stock ideas that match different goals.
- Target potential mispricings by scanning companies that combine strong fundamentals with attractive valuations using the 54 high quality undervalued stocks.
- Strengthen your income focus by reviewing stocks that offer higher yields and aim for resilience with the 12 dividend fortresses.
- Prioritize financial resilience by concentrating on businesses with healthy balance sheets and solid financial foundations through the solid balance sheet and fundamentals stocks screener (46 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com